Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  selumetinib
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
Selumetinib in Treating Younger Patients with Neurofibromatosis Type 1 or Plexiform Neurofibromas That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 18
Trial IDs: 8799, NCI-2013-01491, 110161, 748727, P11809, 11-C-0161, NCT01362803
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU241306I, NCI-2015-00277, 14-008494, NCT02393690
Selumetinib in Treating Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9840, NCI-2015-00456, 16-C-0043, NCT02407405
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00006, NCI-2014-02005, NCT02143466
Selumetinib and Cyclosporine in Treating Patients with Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9571, NCI-2014-01484, 13-2628, NCT02188264
Selumetinib and Nab-Paclitaxel (albumin-stabilized nanoparticle formulation) as Second-Line Treatment in Treating Patients with stage IIIB-IV Non-small Cell Lung Cancer
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00011462, NCI-2015-01018, 11,462, SOL-15008-L, NCT02503358
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1345C00003, NCI-2016-00915, NCT02586987
Start Over